Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8979369 | 1.00 | AR (0.45) | AR | |
| SCHEMBL2330720 | 1.00 | AR (0.45) | AR | |
| Hydrochloric Acid SCHEMBL10575020 | 0.98 | AR (0.44) | AR | |
| SCHEMBL11072789 | 0.83 | AR (0.43) | AR | |
| SCHEMBL10834821 | 0.83 | AR (0.43) | AR | |
| SCHEMBL10434062 | 0.83 | AR (0.43) | AR | |
| SCHEMBL2599597 | 0.79 | AR (0.42) | AR | |
| SCHEMBL10676628 | 0.79 | AR (0.43) | AR | |
| SCHEMBL10434361 | 0.77 | AR (0.36) | AR | |
| SCHEMBL9601583 | 0.76 | AR (0.35) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5644056-A | Method of preparing 7,8-difluoro-2,3-dihydro-3-methyl-4H-1, 4-benzoxazine | HOECHST CELANESE CORPORATION (US) | 1997-07-01 | — | — | US | claimed |
| JP-1261380-A | — | — | None | — | — | JP | disclosed |
| JP-1287086-A | — | — | None | — | — | JP | disclosed |
| JP-1228974-A | — | — | None | — | — | JP | disclosed |
| JP-5246995-A | — | — | None | — | — | JP | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| EP-2172443-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | HAMARI CHEMICALS LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8222452-B2 | Method for producing optically active amines | HAMARI CHEMICALS, LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | HAMARI CHEMICALS, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-4985557-A | OFLOXACIN INTERMEDIATE | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0368410-A3 | OPTICALLY ACTIVE BENZOXAZINES AND BEZOTHIAZINES AND A PROCESS FOR THEIR STEREOSPECIFIC PREPARATION | GIST-BROCADES N.V. (NL) | 1990-09-05 | — | — | EP | disclosed |
| EP-0368410-A2 | Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation | GIST-BROCADES N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
| EP-0368410-A2 | Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation | GIST-BROCADES N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
| JP-H01287086-A | PYRIDOBENZOXAZINES | DAI ICHI SEIYAKU CO LTD | 1989-11-17 | — | — | JP | disclosed |
| US-4880926-A | CRYSTALLIZATION, CAMPHORSULFONIC ACIDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| JP-H01261380-A | SEPARATION OF OPTICAL ISOMER | DAI ICHI SEIYAKU CO LTD | 1989-10-18 | — | — | JP | disclosed |
| JP-H01228974-A | BENZOXADINYL METHLENEMALONATE | DAI ICHI SEIYAKU CO LTD | 1989-09-12 | — | — | JP | disclosed |
| EP-0304684-A1 | Process for the preparation of benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-03-01 | — | — | EP | disclosed |
| EP-0206283-A2 | Optically active pyridobenzoxazine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | AR 4620/4885 |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | INMT, HNMT, PADI3 | AR 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.